Name: Personalized Medicine in Oncology (en Inglés)
SKU: 54771379
Price: 57.21 USD
Availability: InStock
Author: Vanderwalde, Ari

portada Personalized Medicine in Oncology (en Inglés)

Personalized Medicine in Oncology (en Inglés)

Formato

Libro Físico

Ilustrado por

Ari Vanderwalde

Editorial

Mdpi AG

Autor

Vanderwalde, Ari

Idioma

Inglés

N° páginas

190

Encuadernación

Tapa Dura

Dimensiones

24.4x17x1.8 cm

Peso

0.61 kg.

ISBN13

9783036528212

Categorías

Oncología

Personalized Medicine in Oncology (en Inglés)

Ari Vanderwalde (Ilustrado por) · Mdpi AG · Tapa Dura

Libro Nuevo Importado

Envío: 21 a 28 días háb.

$ 114.41$ 57.21

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 57.21

Llega entre el 22 Sep y el 05 Oct a Quito, Pichincha. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Personalized Medicine in Oncology (en Inglés)"

Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first "site-agnostic" drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic "signatures" that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment.